WHO consolidated guidelines on drug-resistant tuberculosis treatment (2019)

2019, 116 pages
ISBN 978 92 890 5446 1
This publication is only available online.

These consolidated guidelines have been updated following Guideline Development Group (GDG) processes carried out between 2011 and 2018 in accordance with WHO requirements. The document replaces other WHO recommendations relating to the treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) issued since 2011 as well as recommendations in other guidelines relevant to the care of drug-resistant TB (DR-TB). The PICO (Population, Intervention, Comparator and Outcomes) questions underlying the recommendations and the revised dosage of medicines used in second-line regimens and key references are included in this document. Document reflect details on the GDG processes and participants, the main methods used to develop the recommendations, the resultant Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence summaries and decision frameworks for each recommendation, and unpublished data, data analysis plans and reports of systematic reviews. The recommendations and other practical information to support their implementation will be reproduced in a forthcoming update of the WHO TB programmatic management handbook.